The Effect of Vitamin D3 Supplementation on the Incidence of Diagnosed Dementia Among Healthy Older Adults-The Finnish Vitamin D Trial.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

The researchers investigated whether vitamin D3 supplementation could affect the incidence of diagnosed dementia in a generally healthy population.

Who Took Part

The study group was 2,492 participants.

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

The study included 2 492 participants from the Finnish Vitamin D Trial, free of diagnosed dementia at baseline.

Incident diagnoses of dementia were obtained from the national care registries.

How the Study Was Run

In design terms this was a randomized and placebo-controlled study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.

What Was Measured

Topics PubMed links to this paper include Cholecalciferol, Dementia, Finland, Dietary Supplements, Incidence and Vitamins.

Author keywords: Cognitive decline, General population and Randomized controlled trial.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 2,492 participants.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2025 (The journals of gerontology. Series A, Biological sciences and medical sciences), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.